Thrombopoietin receptor is required for the oncogenic function of CALR mutants

[1]  C. Pecquet,et al.  Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.

[2]  C. Pecquet,et al.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. , 2016, Blood.

[3]  S. Miyano,et al.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. , 2015, Cancer cell.

[4]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[5]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[6]  M. Cazzola,et al.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. , 2014, Blood.

[7]  F. Passamonti,et al.  JAK inhibitor in CALR-mutant myelofibrosis. , 2014, The New England journal of medicine.

[8]  T. Naoe,et al.  Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation , 2014, Leukemia.

[9]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[10]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[11]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[12]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[13]  M. Cazzola,et al.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms , 2010, Leukemia.

[14]  M. Michalak,et al.  Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. , 2009, The Biochemical journal.

[15]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[16]  D. Kaufman,et al.  Donor cell leukemia: insight into cancer stem cells and the stem cell niche. , 2007, Blood.

[17]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[18]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[19]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[20]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[21]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[22]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[23]  Marek Michalak,et al.  Contrasting functions of calreticulin and calnexin in glycoprotein folding and ER quality control. , 2004, Molecular cell.

[24]  M. Greaves,et al.  Chromosome translocations and covert leukemic clones are generated during normal fetal development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Ana-Teresa Maia,et al.  In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. , 2002, Blood.

[26]  M. Shiseki,et al.  Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source , 2014, Bone Marrow Transplantation.

[27]  D. Norris,et al.  Immunosuppression-Associated Pathology associated lymphoproliferative disorders were observed and entered into the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2012 .